BioCentury
ARTICLE | Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

July 9, 2020 1:27 AM UTC

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19.

The CSL Behring unit of CSL Ltd. (ASX:CSL) began a Phase II trial of garadacimab, a mAb against Factor XIIa, to treat severe respiratory distress in COVID-19 patients with pneumonia. The primary endpoint of the double-blind, placebo-controlled trial is the incidence of tracheal intubation or death...